loading page

Placental Growth Factor in Suspected Preterm Pre-eclampsia: A Review of the Evidence and Practicalities of Implementation
  • +3
  • Alice Hurrell,
  • Alice Beardmore-Gray,
  • Kate Duhig,
  • Louise Webster,
  • Lucy Chappell,
  • Andrew Shennan
Alice Hurrell
King's College London
Author Profile
Alice Beardmore-Gray
King's College London
Author Profile
Kate Duhig
Kings College London
Author Profile
Louise Webster
Kings College London
Author Profile
Lucy Chappell
King's College London
Author Profile
Andrew Shennan
Kings College London
Author Profile

Peer review status:ACCEPTED

11 Mar 2020Submitted to BJOG: An International Journal of Obstetrics and Gynaecology
13 Mar 2020Submission Checks Completed
13 Mar 2020Assigned to Editor
08 Apr 2020Reviewer(s) Assigned
11 May 2020Review(s) Completed, Editorial Evaluation Pending
15 May 2020Editorial Decision: Revise Major
15 Jun 20201st Revision Received
17 Jun 2020Submission Checks Completed
17 Jun 2020Assigned to Editor
06 Jul 2020Review(s) Completed, Editorial Evaluation Pending
09 Jul 2020Editorial Decision: Accept

Abstract

Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented into clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation.